Results 101 to 110 of about 60,195 (236)

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

A Rare Variant of Urothelial Carcinoma: Plasmacytoid Urothelial Carcinoma

Turkiye Klinikleri Journal of Case Reports, 2022
Kazım CEVİZ, Muhammed Emin POLAT, Emre UZUN, Lütfi İhsan BOYACI, Cavit CEYLAN   +4 more
openaire   +1 more source

TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair

Cancer Science, EarlyView.
In hepatocellular carcinoma, the 8q24.3 locus is frequently amplified and is associated with tumor‐specific overexpression of TONSL. TONSL promotes homologous recombination repair through RAD51, limits γH2AX accumulation and apoptosis, supports tumor growth, and its loss increases sensitivity to poly (ADP‐ribose) polymerase (PARP) inhibition.
Akinori Tsujimoto, Hajime Otsu, Takashi Ofuchi, Tomohiko Ikehara, Kosuke Hirose, Shohei Shibuta, Kazuki Omachi, Yu Takahashi, Yuya Ono, Satoshi Higuchi, Takanari Tatsumi, Kiyotaka Hosoda, Qingjiang Hu, Yusuke Yonemura, Takaaki Masuda, Masayuki Sho, Koshi Mimori   +16 more
wiley   +1 more source

Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low‐ and High‐Grade Papillary Urothelial Carcinoma

Cancer Medicine
Background Papillary urothelial carcinoma (transitional cell carcinoma) is one of the most common malignant tumors of the urinary tract. Urothelial carcinomas are classified into muscle‐invasive and non‐muscle‐invasive types.
Natalia Domian, Grzegorz Młynarczyk, Irena Kasacka   +2 more
doaj   +1 more source

First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

Cancer Science, EarlyView.
The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota, Hiroki Ikezawa, Yuko Umetsu, Ken Ito, Abraham Apfel, Yuanqing Ye, Yoshitaka Honma   +15 more
wiley   +1 more source

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Cancer Science, EarlyView.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

Plasmacytoid subtype of urothelial carcinoma – Report of two rare cases and unusual features

Indian Journal of Pathology and Microbiology
Plasmacytoid urothelial carcinoma is a rare but aggressive subtype of urothelial carcinoma. The histopathologic mimics include plasmacytoma, metastasis from invasive lobular breast carcinoma, and gastric signet ring cell carcinoma.
Sagar Ranjan Tripathy, Pavithra Ayyanar, Deepak Kumar Das, Sandip Kumar Barik   +3 more
doaj   +1 more source

SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol

BJU International, EarlyView.
Kevin G. Keane, Richard Gauci, Roslyn J. Francis, Andrew M. Scott, Cynthia Hawks, Andrisha‐Jade Inderjeeth, Ian D. Davis, Jayne Lim, Andrew Redfern, Dickon Hayne   +9 more
wiley   +1 more source

UBE2C‐Mediated CD147‐CTLA‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer

Cancer Science, EarlyView.
UBE2C upregulates cellular CD147 and enhances its release into the tumor microenvironment both as soluble CD147 (sCD147) and packaged within tumor‐derived exosomes. These CD147‐bearing signals induce T‐cell exhaustion, marked by elevated CTLA‐4 expression and reduced secretion of effector cytokines (IFN‐γ, TNF‐α, TGF‐β), ultimately diminishing CD8+ T ...
Xuwei Hong, Ting Hong, Xinyu Liu, Peixiu Yao, Weiqiang Lin, Guoyuan Liu, Huihong Guan, Yonghai Zhang   +7 more
wiley   +1 more source